The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom-Reference-Cited by-同舟云学术

The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom

Published:2019-07-09 Issue:1 Volume:23 Page:86-97
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Floros Lefteris¹,Pagliuca Antonio²,Taie Amer Al³,Weidlich Diana¹,Rita Capparella Maria⁴,Georgallis Mihalina¹,Sung Anita Hor-Yun⁵

Affiliation:

1. Covance Market Access, London, United Kingdom;

2. King’s College Hospital, London, United Kingdom;

3. Pfizer Ltd, Tadworth, UK;

4. Pfizer PIO, Paris, France;

5. Pfizer Inc, New York, NY

Funder

Pfizer

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://tandfonline.com/doi/pdf/10.1080/13696998.2019.1638789

Reference71 articles.

1. ema.europa.eu. [Internet] London: European Medicines Agency; July 2014 [cited Jan 2018]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2014/07/WC500169890.pdf

2. European Medicines Agency; July 2014 [cited Jan 2018]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2014/07/WC500169714.pdf

3. Changing epidemiology of systemic fungal infections

4. Population-Based Analysis of Invasive Fungal Infections, France, 2001–2010

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacoeconomic evaluation of isavuconazole, posaconazole, and voriconazole for the treatment of invasive mold diseases in hematological patients: initial therapy prior to pathogen differential diagnosis in China;Frontiers in Public Health;2023-12-19

2. Real-world Use of Mold-Active Triazole Prophylaxis in the Prevention of Invasive Fungal Diseases: Results From a Subgroup Analysis of a Multicenter National Registry;Open Forum Infectious Diseases;2023-08-07

3. Observed isavuconazole exposure: 5-year experience of azole TDM from a Spanish reference laboratory;Medical Mycology;2023-08

4. Pharmacoeconomic evaluation of isavuconazole, posaconazole and voriconazole in the treatment of invasive fungal infection: initial therapy prior to pathogen differential diagnosis in China;2023-06-09

5. Real-World Financial and Clinical Impact of Diagnostic-Driven and Empirical-Treatment Strategies in High-Risk Immunocompromised Patients with Suspected Aspergillus Infection in the United Kingdom;Microbiology Spectrum;2022-06-29